CD274 and non-small cell lung carcinoma: Previous studies showed that smoking, wild-type EGFR, and absence of liver metastasis predicted longer PFS and increased ORR in NSCLC patients treated with anti-PD-1/PD-L1 antibody (37–39), while acquired resistance to previous EGFR-TKI promoted immune escape (40).